Back

Implications of levels of hyperkalemia in the risk of renin-angiotensin-aldosterone system inhibitors interruption/down-titration and mortality in patients with chronic cardiovascular conditions

22 May 2023 (16:08 - 16:17)
Organised by: Logo
Congress Presentation Part of: Comorbidities Angiotensin-Renin-Bradykinin System HFA Premium Access Heart Failure 2023 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Santiago Jimenez-Marrero

University Hospital of Bellvitge, Barcelona (Spain)

6 More presentations in this session

Presentation thumbnail
Lack of association between celiac disease and idiopathic dilated cardiomyopathy
Doctor G. Cediel Calderon (Tarragona, ES)
Abstract Slides Video
Presentation thumbnail
Hyponatraemia and changes in natraemia during hospitalization for acute heart failure and associations with in-hospital and long-term outcomes - from the ESC Heart Failure Long-Term Registry
Assistant Professor A. Kaplon Cieslicka (Warsaw, PL)
Abstract Slides Video
Presentation thumbnail
Haemodialysis in patients with cardiorenal syndrome: a review of hospital admissions and mortality
Doctor B. Leskovar (Trbovlje, SI)
Abstract Slides Video
Presentation thumbnail
Iron deficiency in heart failure - prevalence, symptoms, functional capacity and health-related quality of life, and outcomes according to different definitions
Mr F. Lindberg (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Effect of finerenone on the incidence of hypokalemia in patients with type 2 diabetes and chronic kidney disease: a FIDELITY analysis
Professor G. Filippatos (Athens, GR)
Abstract Slides Video

Access the full session

Session thumbnail
Comorbidities
Video

The Event

Event poster

Heart Failure 2023

22 May 2023 16:08 CET
You may be interested in
thumbnail
Congress Presentation
Hyperkalemia consequences on the probability of interrupting or lowering renin-angiotensin-aldosterone system inhibitors and risk of hospitalization in patients with chronic cardiovascular conditions
thumbnail
Congress Presentation
Initiation of mineralocorticoid receptor antagonists in patients with cardiorenal diseases: potassium changes, hyperkalaemia risk and discontinuation in the CaRe study
thumbnail
Congress Session
Strategies for managing hyperkalaemia in cardiorenal disease: a clinical dialogue defining a roadmap to improved outcomes

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources